Additionally, the homologous recombination deficiency (HRD) scoring system, which integrates the assessment of BRCA1/2 mutations, loss of heterozygosity (LOH), and tumor mutational burden (TMB), has further expanded the population eligible for PARP inhibitor therapy. This evidence concerns the gene PARP1 and neoplasm.